# EV-201 (NCT03219333)

> A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03219333
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Astellas Pharma Inc
- Conditions: Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Urologic Neoplasms; Renal Pelvis Neoplasms; Urothelial Cancer; Ureteral Neoplasms; Urethral Neoplasms
- Interventions: Enfortumab vedotin
- Enrollment: 219
- Primary outcome: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)

## Commentary we found

- YouTube: 8
- Podcasts: 6
- X threads: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ev-201-nct03219333

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03219333", "email": "<work email>"}; the inbox owner confirms by the emailed link.